Short- and long-term outcomes of endoscopic resection for gastric tube cancer: a Japanese multicenter prospective cohort study
- PMID: 40210015
- DOI: 10.1016/j.gie.2025.04.002
Short- and long-term outcomes of endoscopic resection for gastric tube cancer: a Japanese multicenter prospective cohort study
Abstract
Background and aims: There is limited evidence regarding the use of endoscopic resection for the treatment of gastric tube cancer. We investigated the short- and long-term outcomes of endoscopic resection in patients with gastric tube cancer and compared them with those with naïve stomach cancer.
Methods: This was a secondary analysis of data from a Japanese multicenter prospective cohort study. Data were extracted for all patients who underwent endoscopic resection for gastric tube cancer and naïve stomach cancer. The primary outcome measure was the 5-year overall survival (OS) after endoscopic resection.
Results: A total of 105 patients with gastric tube cancer (113 lesions) and 8460 patients with naïve stomach cancer (9394 lesions) were evaluated. Regarding short-term outcomes, there were no differences in adverse events between the 2 groups. The 5-year OS rate was significantly lower in patients with gastric tube cancer than in those with naïve stomach cancer (71.0% vs 89.5%; P < .001). Multivariate analysis of all-cause mortality revealed that the gastric tube cancer status was a significant factor for poorer OS. None of the patients with gastric tube cancer underwent additional surgery after noncurative resection.
Conclusions: Endoscopic resection could be safely performed for gastric tube cancer; however, its long-term prognosis is worse than that of naïve stomach cancer. Assessing various systemic conditions when deciding on a treatment strategy for gastric tube cancer is important.
Copyright © 2025 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure All authors disclosed no financial relationships. This study was supported by a grant for Clinical Cancer Research from the Japanese Ministry of Health, Labour, and Welfare (H21-022), a grant from Daiwa Securities Health Foundation (H24-16), and grants for the National Cancer Center Research and Development from the Japanese Ministry of Health, Labour, and Welfare (25-A-12, 28-K-1, 29-A-13).
LinkOut - more resources
Full Text Sources